アブストラクト
| Title | No.5 副作用管理 : 腫瘍崩壊症候群 (Tumor Lysis Syndrome : TLS) |
|---|---|
| Subtitle | シリーズ : 抗がん薬治療の副作用 |
| Authors | 宇佐美英績 |
| Authors (kana) | |
| Organization | 大垣市民病院医療安全管理部 |
| Journal | 日本臨床腫瘍薬学会雑誌 |
| Volume | 19 |
| Number | |
| Page | 18-25 |
| Year/Month | 2021 / 4 |
| Article | 報告 |
| Publisher | 日本臨床腫瘍薬学会 |
| Abstract | [POINT] ・腫瘍崩壊症候群の病態を理解する. ・リスク分類と診断基準を理解する. ・予防と治療方法を理解する. 「はじめに」悪性腫瘍またはその治療の結果として, 急速に全身状態の悪化を来し緊急な治療を必要とする状態をoncology emergencyと呼ぶ. 代謝異常, 出血, 頭蓋内圧亢進あるいは血栓塞栓症など適切な介入を要し, 病態・治療を理解しなければならない. 本稿では, oncology emergencyの代表的な疾患のひとつである腫瘍崩壊症候群 (tumor lysis syndrome : TLS) について概説する. これまでTLS発症が稀とされてきた固形腫瘍においても, 分子標的薬など抗腫瘍効果の高い治療薬が多数登場し治療体系が大きく変化している. TLSにより重篤な転機となる可能性もあるため, 薬剤師も病態, リスク, 予防および治療方法を理解しなければならない. 新規薬剤の開発が目覚ましい今, TLSに対する再認識が必要である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome(TLS)in adults and children with malignant diseases: an expert TLS panel consensus, Br J Haematol 2010; 149(4): 578-586.
- 2) Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM: Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia, J Clin Oncol 1998; 16(7): 2313-2320.
- 3) Ali M, Steven T, Nadine B, Tara KG, Scott CH: Managing tumor lysis syndrome in the era of Novel cancer therapies, J Adv Pract Oncol 2017; 8(7): 705-720.
- 4) Gemici C: Tumour lysis syndrome in solid tumours, Clin Oncol(R Coll Radiol) 2006; 18(10): 773-780.
- 5) Yen TH, Chang CH, Shiu SI: Tumor lysis syndrome after combination therapy of nivolumab and sorafenib in a woman with advanced hepatocellular carcinoma, Case Rep Gastroenterol 2020; 14(2): 367-372.
残りの22件を表示する
- 6) Sosipatros AB, Patrick MF, Souvik C, Christine LH: Tumor lysis syndrome in limited-stage small-cell lung cancer, J Thorac Oncol 2013; 8(7): e61-e62.
- 7) Baudon C, Duhoux FP, Sinapi I, Canon JL: Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: A case report, J Med Case Reports 2016; 10(1): 178.
- 8) Cihan S, Atasoy A, Yildirim Y, Babacan NA, Kos TF: Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid? Tumori 2015; 101(2): e40-e45.
- 9) Regnault MM, Ofaiche J, Boulinguez S, Tournier E, Rochaix P, Paul C, Lamant L, Meyer N: Tumour lysis syndrome: An unexpected adverse event associated with ipilimumab, J Eur Acad Dermatol Venereol 2017; 31(2): e73-e74.
- 10) Doi M, Okamoto Y, Yamauchi M, Naitou H, Shinozaki K: Bleomycin-induced pulmonary fibrosis after tumor lysis syndrome in a case of advanced yolk sac tumor treated with bleomycin, etoposide and cisplatin(BEP)chemotherapy, Int J Clin Oncol 2012; 17(5): 528-531.
- 11) Qian KQ, Ye H, Xiao YW, Bao YY, Qi CJ: Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay(ATP-TCA), Int J Gen Med 2009; 2: 1-4.
- 12) Noh GY, Choe DH, Kim CH, Lee JC: Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer, J Clin Oncol 2008; 26(36): 6005-6006.
- 13) Aline B, Felipe S, Andre L, Regis O, Paula F, Anamaria A, Diogo A: Tumor lysis syndrome after platinum-based chemotherapy in castration-resistant prostate cancer with a BRCA2 mutation: A Case report, Clin Genitourin Cancer 2019; 17(1): e61-e64.
- 14) Faisal F, Diego V, Kofi MO: A case report of atezolizumab induced tumor lysis syndrome, Am J Case Rep 2019; 20: 785-789.
- 15) Carrier X, Gaur S, Philipovskiy A: Tumor lysis syndrome after a single dose of atezolizumab with nab-paclitaxel: A Case Report and Review of Literature, Am J Case 2020; 21: e925248.
- 16) Oiwa K, Morita M, Kishi S, Okura M, Tasaki T, Matsuda Y, Tai K, Hosono N, Ueda T, Yamauchi T: High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib, Anticancer Res 2016; 36(12): 6655-6662.
- 17) Fengbo J, Mingzhen Y, Yingying C, Lei J, Lixia L: Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report, Medicine(Baltimore) 2020; 99(45): e22632.
- 18) Douglas KA, Humes HD: A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma, Clin Nephrol Case Stud 2017; 5(1): 78-81.
- 19) John FS, Thomas JK, Barbara E, Peter H, James D, Sarit A, Carolyn O, John G, Tadeusz R, Javier D, Ulrich J, Guillaume C, Marco M, Rod H, Elizabeth AP, Yan L, Michelle B, Kathryn H, Mehrdad M, Arnon PK: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia, N Engl J Med 2018; 378(12): 1107-1120.
- 20) Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, Bahceci E, Kaneko M, Kusano M, Yamada S, Takeshita S, Miyawaki S, Naoe T: Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study, Cancer Sci 2018; 109(10): 3235-3244.
- 21) Kum JL, Vivian C, Ashley W, Sunil T, Ibrahim A, Mojtaba A: Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults, Ther Clin Risk Manag 2016; 12: 1301-1310.
- 22) Gail LJ, Andrew W, Graham HJ, Nicholas JA, Simon R; British Committee for Standards in Haematology: Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology, Br J Haematol 2015; 169(5): 661-671.
- 23) Sonbol MB, Yadav H, Vaidya R, Rana V, Witzig TE: Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase, Am J Hematol 2013; 88(2): 152-154.
- 24) Ishizawa K, Ogura M, Hamaguchi M, Hotta T, Ohnishi K, Sasaki T, Sakamaki H, Yokoyama H, Harigae H, Morishima Y: Safety and efficacy of rasburicase(SR29142)in a Japanese phase II study, Cancer Sci 2009; 100(2): 357-362.
- 25) Jorge C, Joseph OM, Richard TM, Meir W, Michael C, Jeffrey M, Selina L, Bimalangshu RD, Gary JS, Dat P, Camille NA, Muthuswamy K, Archie BJ, Abderrahmane L, Karen S: Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-Results of a multicenter phase III study, J Clin Oncol 2010; 28(27): 4207-4213.
- 26) Usami E, Kimura M, Iwai M, Teramachi H, Yoshimura T: Analysis of the Incidence of Tumor Lysis Syndrome in Patients with Hematologic Malignancies Treated with Rasburicase, Mol Clin Oncol 2017; 6(6): 955-959.
- 27) Darmon M, Vincent F, Camous L, Canet E, Bonmati C, Braun T, Caillot D, Cornillon J, Dimicoli S, Etienne A, Galicier L, Garnier A, Girault S, Hunault-Berger M, Marolleau J, Moreau P, Raffoux E, Recher C, Thiebaud A, Thieblemont C, Azoulay E; Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique(GRRR-OH): Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique, Br J Haematol 2013; 162(4): 489-497.
